Why the study?
Does BAY y 5959 improve myocardial function without adverse chronotropic effects compared to isoproterenol in isolated normal and failing dog hearts?
Does BAY y 5959 improve myocardial function without adverse chronotropic effects compared to isoproterenol in isolated normal and failing dog hearts?
Answers are grounded in this paper and cite their sources.
BAY y 5959 demonstrates preserved inotropic effects without increasing heart rate in a canine model of heart failure, suggesting potential advantages over traditional beta-adrenergic agonists.
BAY y 5959 is a dihydropyridine derivative with positive inotropic actions mediated by a direct increase in intracellular calcium. We characterized the direct myocardial actions of this new agent in hearts isolated from seven normal dogs and from five dogs with repeated coronary microembolization-induced heart failure. Inotropic actions of BAY y 5959 were accompanied by little effect on duration of contraction and by prolongation of the monophasic action potential (MAP); in contrast, isoproterenol decreased contraction and MAP durations. Whereas inotropic responsiveness to isoproterenol was blunted in embolized hearts, these actions of BAY y 5959 were relatively preserved in the heart failure state. Isoproterenol increased heart rate, whereas BAY y 5959 had little effect. Changes in coronary vascular resistance also decreased similarly for isoproterenol and BAY y 5959. Finally, for comparable inotropy, increases in myocardial oxygen consumption were similar for isoproterenol and for BAY y 5959. In summary, preserved inotropic responsiveness and lack of positive chronotropic actions are two clinically favorable features of this type of inotropic agents compared with a typical beta-adrenergic agonist.
No takes yet. Share an insight, caveat, or question.
Todaka et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: